Protection When And Where It’s Needed
|XenMatrix™ AB is the first antibacterial-coated, non-crosslinked porcine dermal graft proven to inhibit the colonization of MRSA, E. coli, and other bacteria in preclinical models.1,2 It uses a combination of well-characterized antibiotics, Rifampin and Minocycline, to offer an unmatched level of graft protection in challenging ventral hernia repair.|
Protective Antibacterial Coating
The XenMatrix™ AB coating uses Rifampin and Minocycline, an antibacterial combination with demonstrated clinical results in other medical devices.3
- Protects the graft prior to neovascularization.
- Provides protection from biofilm formation caused by MRSA and E. coli.
- Shown to reduce bacterial colonization in 5 different medical devices:
– Central Venous Catheters (CVC) – External Ventricular Drain Catheters (EVD)
– Hemodialysis Catheters – Inflatable Penile Prostheses (IPP)
– Cardiovascular Implantable Electronic
Device (CIED) Envelopes
• These devices coated with Rifampin and Minocycline are well-studied in clinical literature; 30
publications including 67,000 patients and 6 randomized controlled trials.3
– No instances of microbial resistance to the combination of Rifampin and Minocycline have been
– No complications or adverse events due to the antibiotic content for on-label use have been
1IMS Data, Q2 2014, 510K search, fda.gov.
2Preclincal data on file; results may not correlate to clinical performance.
3 Literature search and analysis of Rifampin and Minocycline coated medical devices. Data on file. 2014